NASDAQ
NRXP

NRX Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

NRX Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$0.25
Today's High:
$0.2761
Open Price:
$0.2761
52W Low:
$0.221
52W High:
$1.54
Prev. Close:
$0.262
Volume:
663327

Company Statistics

Market Cap.:
$24.35 million
Book Value:
-0.035
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-87.1%
Return on Equity TTM:
-346.7%

Company Profile

NRX Pharmaceuticals Inc had its IPO on 2017-12-04 under the ticker symbol NRXP.

The company operates in the Healthcare sector and Biotechnology industry. NRX Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of NRX Pharmaceuticals Inc opened at $0.28 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.25 - $0.28, and closed at $0.26.

This is a -0.38% slip from the previous day's closing price.

A total volume of 663,327 shares were traded at the close of the day’s session.

In the last one week, shares of NRX Pharmaceuticals Inc have slipped by -12.42%.

NRX Pharmaceuticals Inc's Key Ratios

NRX Pharmaceuticals Inc has a market cap of $24.35 million, indicating a price to book ratio of 4.5546 and a price to sales ratio of 0.

In the last 12-months NRX Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-36399000. The EBITDA ratio measures NRX Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, NRX Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -87.1% with a return of equity of -346.7%.

In Q2, NRX Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

NRX Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.52 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NRX Pharmaceuticals Inc’s profitability.

NRX Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.6134. Its price to sales ratio in the trailing 12-months stood at 0.

NRX Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$19.81 million
Total Liabilities
$22.62 million
Operating Cash Flow
$2000.00
Capital Expenditure
$2000
Dividend Payout Ratio
0%

NRX Pharmaceuticals Inc ended 2024 with $19.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $19.81 million while shareholder equity stood at $-2808000.00.

NRX Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $22.62 million in other current liabilities, 80000.00 in common stock, $-242753000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.97 million and cash and short-term investments were $14.97 million. The company’s total short-term debt was $12,692,000 while long-term debt stood at $0.

NRX Pharmaceuticals Inc’s total current assets stands at $19.79 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $6000.00 compared to accounts payable of $2.21 million and inventory worth $-6000.00.

In 2024, NRX Pharmaceuticals Inc's operating cash flow was $2000.00 while its capital expenditure stood at $2000.

Comparatively, NRX Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.26
52-Week High
$1.54
52-Week Low
$0.221
Analyst Target Price
$4.67

NRX Pharmaceuticals Inc stock is currently trading at $0.26 per share. It touched a 52-week high of $1.54 and a 52-week low of $1.54. Analysts tracking the stock have a 12-month average target price of $4.67.

Its 50-day moving average was $0.35 and 200-day moving average was $0.75 The short ratio stood at 1.96 indicating a short percent outstanding of 0%.

Around 3602.5% of the company’s stock are held by insiders while 423.2% are held by institutions.

Frequently Asked Questions About NRX Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of NRX Pharmaceuticals Inc is NRXP

The IPO of NRX Pharmaceuticals Inc took place on 2017-12-04

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$25.65
-0.42
-1.61%
$27.65
0.14
+0.51%
$525.6
-19.3
-3.54%
$322
-27.55
-7.88%
Jfrog Ltd (FROG)
$26.45
-0.45
-1.67%
$2.85
0.05
+1.79%
$28.8
0.05
+0.17%
$3.6
0
0%
$361.85
-7.85
-2.12%
$3.9
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Address

1201 Orange Street, Wilmington, DE, United States, 19801